Physician profile
John A Dieck
NPI 1427059310
$5,753.32
in general payments reported to CMS, 2019-2025
35 companies · $504 in 2025
The $504 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,468 · 2020: $494 · 2021: $666 · 2022: $753 · 2023: $768 · 2024: $1,099 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,139 · Consulting Fee: $200 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,138.98 |
| Consulting Fee | $200.00 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $941.33 | 2020-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Aveir, Assurity |
| Abiomed | $660.51 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $569.81 | 2019-2025 | Uptravi |
| Novartis Pharmaceuticals Corporation | $513.62 | 2020-2025 | |
| Pfizer INC. | $422.32 | 2022-2025 | |
| Impulse Dynamics (USA) INC. | $302.17 | 2021-2023 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $274.69 | 2022-2024 | Camzyos, Eliquis |
| Amgen INC. | $224.14 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $210.36 | 2024-2025 | Verquvo, Winrevair |
| Bayer Healthcare Pharmaceuticals INC. | $200.00 | 2024 | |
| Intuitive Surgical, INC. | $186.61 | 2019 | |
| Vifor Pharma, INC. | $171.63 | 2020 | |
| Sanofi-Aventis U.S. LLC | $124.86 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $110.02 | 2019-2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $106.94 | 2019-2024 | Xarelto |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $80.55 | 2022-2025 | Ozempic, Wegovy |
| Cvrx, INC. | $76.26 | 2024 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $74.69 | 2019-2023 | Brilinta |
| Cardiva Medical, INC. | $74.52 | 2022 | |
| Boston Scientific Corporation | $69.71 | 2019-2025 | Watchman Flx |
| Siemens Medical Solutions USA, INC. | $50.03 | 2023 | Artis Icono Floor |
| Amarin Pharma, INC. | $43.16 | 2019 | |
| Spinal Simplicity, LLC | $32.89 | 2025 | Ha Minuteman G3-R |
| Acist Medical Systems, INC. | $31.27 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $29.26 | 2025 | Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $24.85 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $22.75 | 2021 | |
| Cordis US Corp. | $21.69 | 2025 | Mynx Control |
| Agepha Pharma Fz LLC | $20.28 | 2024 | Lodoco |
| Innovation Technologies INC | $16.06 | 2025 | Irrisept |
| Cook Medical LLC | $14.63 | 2019 | |
| Scpharmaceuticals INC. | $14.56 | 2024 | |
| Stryker Corporation | $13.55 | 2025 | Flowtriever |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.50 | 2021 | |
| Medtronic Vascular, INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dieck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.